Analytical challenges in nanomedicine

Kranz, Christine; Eaton, Douglas C.; Mizaikoff, Boris

doi:10.1007/s00216-010-4631-6

Cited by 15 publications

(9 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In turn, scientists working in nanotechnology may not be aware of the most pertinent questions and analytical challenges to be addressed in cell physiology or -more generallyin biomedicine [15]. Traditionally, experts in cellular signalling and signal transduction are well versed in applying biochemical methods and molecular approaches to biological problems relevant to health sciences.…”

Section: Nanoscale Methods In Biotechnology and Medicinementioning

confidence: 99%

Nanotechnology and Analytical Chemistry

Adams¹,

Barbante²

2015

Chemical Imaging Analysis

View full text Add to dashboard Cite

Section: Nanoscale Methods In Biotechnology and Medicinementioning

confidence: 99%

Nanotechnology and Analytical Chemistry

Adams¹,

Barbante²

2015

Chemical Imaging Analysis

View full text Add to dashboard Cite

“…Optimized nanomedicines have been administrated through various routes and their efficacy has been assessed using advanced assays and analytical methods [66]. The outcomes suggest that the efficient delivery and release of nanomedicine is crucial and also increase the demand for novel brain delivery methods [66]. Maintaining the appropriate level of therapeutics in the brain for a longer duration remains a challenge.…”

Section: Challenges and Alternative Approachesmentioning

confidence: 99%

Personalized nanomedicine for CNS diseases

Kaushik

Jayant

Bhardwaj

et al. 2018

Drug Discovery Today

View full text Add to dashboard Cite

Central nervous system (CNS) diseases are rapidly increasing globally. Currently used therapeutic agents to treat CNS diseases exhibit significant efficacy. However, the inability of these drugs to cross the blood-brain barrier (BBB) and invasiveness of the technologies to achieve localized drug delivery in disease-specific parts of the brain have thwarted pain-free and complete treatment of CNS diseases. Therefore, the safe, non-invasive, and targeted delivery of drugs to the brain using nanoparticles (NPs) is currently receiving considerable research attention. Here, we highlight advances in state-of-the-art personalized nanomedicine for the treatment of CNS diseases (with a focus on dementia), the related challenges, possible solutions, and prospects for nano-enabled personalized medicine.

show abstract

“…Nanomedicines are associated with fewer side effects, as they reduce the distribution of the drug to nontarget organs or tissues. The popularity and increasing use of nanoparticles has made it necessary to develop a simple and fast analytical method to ensure quality and safety [5][6][7]. These methods must address the quantity of nanoparticles in a preparation and determine how much drug has been encapsulated within those nanoparticles.…”

Section: Introductionmentioning

confidence: 99%

Rapid evaluation of the quantity of drugs encapsulated within nanoparticles by high-performance liquid chromatography in a monolithic silica column

2015

View full text Add to dashboard Cite

Drug-containing nanoparticles, the foundation of nanomedicine, provide promise for the safe and effective delivery of drugs to their targets. In this study, we developed a simple method to determine the relative quantities of nanoparticle-encapsulated drugs by HPLC using a commercially available monolithic silica column. Amphotericin B- and irinotecan-containing nanoparticles produced nearly simultaneous elution peaks (~7 min), suggesting that elution was largely driven by hydrodynamic effects and was relatively unaffected by differences in the encapsulated drug. A good correlation was observed between the intensity of the nanoparticle peak and the relative quantity of encapsulated drug. We used our method to characterize the effects of drug quantity and nanoparticle size on drug encapsulation rates within the nanoparticles. Encapsulation increased with increasing quantities of the drug in the preparation solution. This effect was greater for irinotecan than for amphotericin B. Although absolute encapsulation also increased with increasing nanoparticle size, encapsulation efficiency decreased. Thus, the monolith column is suitable for evaluating nanomedicine quality and may be used to evaluate many kinds of nanomaterials. Graphical Abstract Evaluation method of quantity of drug encapsulated within nanoparticles was developed. The method can be applicable for a rapid quality assurance of nanomedicine.

show abstract

Analytical challenges in nanomedicine

Cited by 15 publications

References 5 publications

Nanotechnology and Analytical Chemistry

Nanotechnology and Analytical Chemistry

Personalized nanomedicine for CNS diseases

Rapid evaluation of the quantity of drugs encapsulated within nanoparticles by high-performance liquid chromatography in a monolithic silica column

Contact Info

Product

Resources

About